8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): August 1, 2005

                           ARIAD Pharmaceuticals, Inc.
             (Exact name of registrant as specified in its charter)


          Delaware                  0-21696                   22-3106987
(State or other jurisdiction      (Commission              (I.R.S. Employer
      of incorporation)           File Number)            Identification No.)


              26 Landsdowne Street, Cambridge, Massachusetts 02139
               (Address of principal executive offices) (Zip Code)


       Registrant's telephone number, including area code: (617) 494-0400


                                 Not Applicable
          (Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))







ITEM 8.01  Other Events.

On August 1, 2005, ARIAD Pharmaceuticals, Inc. (the "Company") issued a press
release announcing its intention to publicly offer 6,000,000 shares of its
common stock pursuant to its effective shelf registration statement previously
filed with the Securities and Exchange Commission. Lehman Brothers Inc. is
acting as sole book running manager for the offering, and Lazard Capital Markets
LLC and SG Cowen & Co., LLC are acting as co-managers. The Company also intends
to grant the underwriters an option to purchase up to an additional 900,000
shares of common stock within 30 days after the offering if the underwriters
sell more than 6,000,000 shares in the offering. The information contained in
the press release dated August 1, 2005, is incorporated herein by reference and
attached to this Current Report on Form 8-K as Exhibit 99.1 hereto.

ITEM 9.01  Financial Statements and Exhibits.

      (c)  The following exhibits are filed with this report

           Exhibit
           Number            Description
           -------           -----------

           99.1              The Registrant's press release dated August 1, 2005
                             announcing a public offering.





                                       2





                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                           ARIAD Pharmaceuticals, Inc.



                           By: /s/ Edward M. Fitzgerald
                              --------------------------------------------------
                               Edward M. Fitzgerald
                               Senior Vice President and Chief Financial Officer


Date: August 1, 2005



                                       3





                                  EXHIBIT INDEX
                                  -------------

Exhibit
Number           Description
- -------          -----------

99.1             The Registrant's press release dated August 1, 2005 announcing
                 a public offering.




                                       4

EX-99.1

                                                                    EXHIBIT 99.1
                                                                    ------------

            ARIAD Announces Proposed Public Offering of Common Stock

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 1, 2005--ARIAD
Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that it is filing
a prospectus supplement with the Securities and Exchange Commission
related to an underwritten public offering of 6,000,000 shares of
common stock under an existing shelf registration statement. The
underwriters have been granted the option to purchase up to an
additional 900,000 shares if they sell more than 6,000,000 shares in
the offering. All of the shares are being sold by ARIAD.
    Lehman Brothers Inc. is acting as sole book-running manager in
this offering. Lazard Capital Markets LLC and SG Cowen & Co., LLC are
acting as co-managers.

    This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities, nor shall there
be any sale of the securities in any state in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state. A
prospectus supplement relating to these securities is being filed with
the Securities and Exchange Commission. This offering of the shares of
common stock may be made only by means of the prospectus supplement
and related prospectus, a copy of which is available from Lehman
Brothers, Inc., Prospectus Department, c/o ADP Financial Services,
Integrated Distribution Services, 1155 Long Island Avenue, Edgewood,
New York 11717, monica_castillo@adp.com or at the Securities and
Exchange Commission's website at www.sec.gov.

    ARIAD is engaged in the discovery and development of breakthrough
medicines to treat cancer by regulating cell signaling with small
molecules.

    CONTACT: ARIAD Pharmaceuticals, Inc.
             Edward Fitzgerald (Investors)
             617-621-2345
             or
             Pure Communications
             Andrea Johnston (Media)
             910-616-5858